Recombinant Human NG2/MCSP/CSPG4 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human NG2/MCSP/CSPG4 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit neurite outgrowth of dissociated E13 chick embryonic dorsal root ganglia (DRG) neurons. Able to significantly inhibit neurite outgrowth when immobilized as a 3 μL droplet containing 90 ng on a nitrocellulose coated microplate.
• Source: Mouse myeloma cell line, NS0-derived human NG2/MCSP protein
  Ser1583-Ser2224, with a C-terminal 6-His tag
• Accession #: Q6UVK1
• N-terminal Sequence: Ser1583
• Protein/Peptide Type: Recombinant Proteins
• Gene: CSPG4
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 69 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 100-110 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 300 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human NG2/MCSP/CSPG4 Protein, CF

• AN2
• chondroitin sulfate proteoglycan 4 (melanoma-associated)
• chondroitin sulfate proteoglycan 4
• CSPG4
• EC 3.6.3
• HMW-MAA
• MCSP
• MCSPChondroitin sulfate proteoglycan NG2
• MCSPG
• MCSPGMelanoma chondroitin sulfate proteoglycan
• MEL-CSPG
• MSK16Melanoma-associated chondroitin sulfate proteoglycan
• NG2
• NG2EC 2.7.8

Background

NG2, also known as CSPG4, MCSP, and AN2, is a 400-500 kDa transmembrane chondroitin sulfate proteoglycan (CSPG) with a protein core of approximately 300 kDa. The extracellular region can be proteolytically shed from the cell surface (1-3). Mature human NG2 consists of a 2195 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 77 aa cytoplasmic domain (4). Within aa 1583-2224, human NG2/CSPG4 shares 83% aa sequence identity with mouse and rat CSPG4. NG2 binds to the extracellular matrix proteins Laminin, Tenascin, and Collagens II, V, and VI as well as to the growth factors FGF-2 and PDGF-AA (1, 5, 6). NG2 is expressed on glial cell progenitors known as O2A cells or NG2 glia (2, 7, 8). These cells are neuronally responsive and differentiate primarily into oligodendrocytes but also into astrocytes (8-10). NG2 associates with PDGF R alpha and the AMPA R subunit GluR2 (2, 7). It is up-regulated on microglial cells during inflammation and contributes to the induction of inflammatory mediators (11). Various CSPGs in the brain inhibit neurite outgrowth through interactions with Nogo Receptor/NgR1 and NgR3 (12). This recombinant protein product corresponds to the last 5 CSPG repeats, a region which can independently inhibit neurite outgrowth (13). NG2 is also expressed on vascular mural cells and capillaries (10, 14). It promotes vascular endothelial cell (EC) migration and angiogenesis through interactions with Galectin-3 and Integrin alpha 3 beta 1 on EC, Plasminogen, and Angiostatin (15, 16). NG2 is also expressed on a variety of tumors where it contributes to tumor cell adhesion, motility, and invasion (17).

1. Campoli, M. et al. (2010) Adv. Cancer Res. 109:73.
2. Nishiyama, A. et al. (1996) J. Neurosci. Res. 43:315.
3. Nishiyama, A. et al. (1995) Mol. Biol. Cell 6:1819.
4. Pluschke, G. et al. (1996) Proc. Natl. Acad. Sci. USA 93:9710.
5. Burg, M.A. et al. (1996) J. Biol. Chem. 271:26110
6. Goretzki, L. et al. (1999) J. Biol. Chem. 274:16831.
7. Stegmuller, J. et al. (2003) J. Biol. Chem. 278:3590.
8. Komitova, M. et al. (2009) J. Comp. Neurol. 512:702.
9. Bergles, D.E. et al. (2000) Nature 405:187.
10. Zhu, X. et al. (2008) Development 135:145.
11. Gao, Q. et al. (2010) Neuroscience 165:386.
12. Dickendesher, T.L. et al. (2012) Nat. Neurosci. 15:703.
13. Ughrin, Y.M. et al. (2003) J. Neurosci. 23:175.
14. Schlingemann, R.O. et al. (1990) Am. J. Pathol. 136:1393.
15. Fukushi, J. et al. (2004) Mol. Biol. Cell 15:3580.
16. Goretzki, L. et al. (2000) J. Biol. Chem. 275:28625.
17. Wang, X. et al. (2010) Curr. Mol. Med. 10:419.

Publications for NG2/MCSP (2585-PG)(2)

Publications using 2585-PG

• L Lopez-Cara, J Martorell-, P Carmona-Sá, E Gonzalez-M iPS-Derived Early Oligodendrocyte Progenitor Cells from SPMS Patients Reveal Deficient In Vitro Cell Migration Stimulation Cells, 2020-07-29;9(8):. 2020-07-29 [PMID: 32751289] (Bioassay, Human)
• S Lykkemark, OA Mandrup, MB Jensen, J Just, P Kristensen A novel excision selection method for isolation of antibodies binding antigens expressed specifically by rare cells in tissue sections Nucleic Acids Res., 2017-06-20;0(0):. 2017-06-20 [PMID: 28369551] (ELISA (Standard), Human)

Bioinformatics

• Gene Symbol: CSPG4
• Uniprot:
  • Q6UVK1()